• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pronutria launches two clinical trials

Pronutria launches two clinical trials

February 14, 2014
CenterWatch Staff

Pronutria, a company a discovery engine and pipeline of pharmaconutrient products, has announced the beginning of two clinical trials evaluating its lead ProNutrein product candidates. The company is utilizing its ProNutrein discovery platform to identify and develop protein pharmaconutrients, protein nutrients identified in food with beneficial impact in many areas of human health, including muscle, metabolic and gastrointestinal health. Pronutria also announced the closing of a $12.25 million financing that will fund the advancement of the ProNutrein pipeline as well as the development of additional candidates as medical foods and supplements, and in a separate business unit, as therapeutics.

Pronutria's two clinical studies are evaluating its lead ProNutrein candidates for beneficial effects on muscle and metabolism in age appropriate healthy volunteers. In relevant preclinical models of muscle growth and thermogenesis, these candidates have demonstrated substantial efficacy. Pronutria is evaluating these lead programs for development as nutritional supplements and medical foods, and is building off published, positive clinical amino acid data. The company expects to complete these trials by the end of the second quarter of 2014.

"These trials demonstrate our unique ability to advance multiple lead ProNutrein candidates from product conception to human data in multiple indications in less than a year in a highly capital efficient manner," said Robert Connelly, CEO of Pronutria. "Pronutria's understanding of amino acid pharmacology has positioned us to rapidly build a pipeline of orally administered protein products that can have life changing benefits for millions."

Pronutria was founded in 2011 by Flagship VentureLabs, the innovation foundry of Flagship Ventures. The $12.25 million Series B financing was led by Flagship and includes private investors. Pronutria expects to fund its activities through a combination of partnerships and investment. The company has raised $23 million to date.

"Pronutria has very effectively converted its unique vision into reality with multiple clinical candidates," said Dr. Noubar Afeyan, chairman of Pronutria and managing partner and CEO of Flagship Ventures. "The company has hit an important inflection point with a validated platform where it will rapidly advance its candidates in important medical areas initially as medical foods and dietary supplements and eventually as therapeutics."

Pronutria is unlocking the untapped potential of the individual proteins in the human diet to impact human health. The company's ProNutrein platform delivers single proteins orally that, through the normal digestive process, release specific combinations of amino acids. Over 40 years of clinical trial work has validated the impact of specific amino acids on a range of important conditions including muscle loss, metabolic disease and rare genetic diseases. Delivering these validated amino acid combinations in protein form couples the clinical benefit with physiochemical and pharmacokinetic control.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing